Abstract
Naloxone, an FDA approved opioid inhibitor, used to reverse opioid overdose complications has up till date faced challenges associated with its delivery. Limitations include the use of invasive delivery forms and the need for frequent redosing due to its short half-life. Further, the use of the non-invasive commercially available intranasal form is faced with limitations such as nasal epistaxis and inability to use the intranasal channel due to nasal trauma common in addicts from frequent drug snorting. The goal of the current study was to design a rapidly dissolving polymeric microneedle (MN) patch with delivery and pharmacokinetic properties comparable to that seen with the commercially available NAL products, eliminating their highlighted limitations. Factors such as drug loading and polymer strength influenced the fabrication of the MNs. Compared to passive permeation, a reduced lag time of about 5-15 min was observed with a significant drug flux of 15.09 ± 7.68 μg/cm2/h seen in the first 1 h (p<0.05) with an array of 100 needles (500 µm long). Increasing the MN length and density (no. of needles/unit area) made a significant difference in the amount permeated and flux (p<0.05), with latter being more influential. Further, through a mechanistic model of drug release from the patch, integrated with pharmacokinetic modeling, we optimized the design of the patch to reproduce in-silico the clinical pharmacokinetics of NAL obtained through commercial intramuscular and intranasal devices. Model simulations and analyses revealed the significance of needle base diameter and needle count in improving systemic pharmacokinetics of NAL.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research work was partially funded by American Association of Colleges of Pharmacy via New Investigator Award 2020:2021 (AP). This research has also been supported in part by the Cockrell Foundation (PD, VC), and by the National Science Foundation Grant DMS-1930583 (ZW, VC), the National Institutes of Health (NIH) Grants 1R01CA253865 (ZW, VC), 1U01CA196403 (ZW, VC), 1U01CA213759 (ZW, VC), 1R01CA226537 (ZW, VC), and 1R01CA222007 (ZW, VC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Abbreviations
- CLSM
- Confocal laser scanning microscopy
- FDA
- Food and Drug Administration
- GSA
- Global sensitivity analysis
- HIV/AIDS
- Human immune deficiency syndrome/Acquired immune deficiency syndrome
- HPLC
- High performance liquid chromatography
- NAL
- Naloxone
- NIDA
- National Institute on Drug Abuse
- MN
- Microneedle
- IE
- Insertion efficiency
- IN
- Intranasal
- IM
- Intramuscular
- IV
- Intravenous
- LSA
- Local sensitivity analysis
- GSA
- Global sensitivity analysis
- PBS
- Phosphate buffered saline
- PDMS
- Polydimethylsiloxane
- PK
- Pharmacokinetics
- PVP
- Polyvinylpyrrolidone
- SC
- Stratum corneum
- TFA
- Trifluoroacetic acid
